ARMC12

Summary

ARMC12 (armadillo repeat containing 12, HGNC:21099) is a protein-coding gene on chromosome 6p21.31, encoding Armadillo repeat-containing protein 12 (Q5T9G4). Essential for male fertility and sperm mitochondrial sheath formation.

Involved in positive regulation of cell growth and sperm mitochondrial sheath assembly. Located in nucleus. Implicated in spermatogenic failure 90.

Source: NCBI Gene 221481 — RefSeq curated summary.

At a glance

• GWAS associations: 4
• Clinical variants (ClinVar): 64 total — 3 pathogenic
• Phenotypes (HPO): 7
• MANE Select transcript: NM_001286574

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:21099
Approved symbol	ARMC12
Name	armadillo repeat containing 12
Location	6p21.31
Locus type	gene with protein product
Status	Approved
Aliases	FLJ25390
Ensembl gene	ENSG00000157343
Ensembl biotype	protein_coding
OMIM	620377
Entrez	221481

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 3 protein_coding, 1 nonsense_mediated_decay

ENST00000288065, ENST00000373866, ENST00000373869, ENST00000471400

RefSeq mRNA: 3 — MANE Select: NM_001286574 NM_001286574, NM_001286576, NM_145028

CCDS: CCDS4809, CCDS69093, CCDS69094

Canonical transcript exons

ENST00000373866 — 6 exons

Exon	Start	End
ENSE00001031991	35738384	35738518
ENSE00001031993	35747576	35747647
ENSE00001031998	35738027	35738172
ENSE00001032005	35747261	35747434
ENSE00001810185	35737032	35737271
ENSE00001828655	35748538	35749079

Expression profiles

Bgee: expression breadth ubiquitous, 160 present calls, max score 94.77.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.0932 / max 92.9235, expressed in 3 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
67465	0.0417	3
67466	0.0298	3
67464	0.0157	3
67463	0.0060	3

Top tissues by expression

252 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right testis	UBERON:0004534	94.77	gold quality
left testis	UBERON:0004533	94.40	gold quality
testis	UBERON:0000473	91.20	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	87.43	gold quality
adenohypophysis	UBERON:0002196	82.81	gold quality
sperm	CL:0000019	81.73	gold quality
pituitary gland	UBERON:0000007	80.71	gold quality
right lobe of liver	UBERON:0001114	76.03	gold quality
left uterine tube	UBERON:0001303	73.32	gold quality
left ovary	UBERON:0002119	73.11	gold quality
right ovary	UBERON:0002118	72.90	gold quality
right adrenal gland	UBERON:0001233	71.43	gold quality
right lobe of thyroid gland	UBERON:0001119	71.38	gold quality
right adrenal gland cortex	UBERON:0035827	70.70	gold quality
left lobe of thyroid gland	UBERON:0001120	70.17	gold quality
nucleus accumbens	UBERON:0001882	70.14	gold quality
mucosa of stomach	UBERON:0001199	69.53	gold quality
lower esophagus muscularis layer	UBERON:0035833	69.53	gold quality
lower esophagus	UBERON:0013473	69.48	gold quality
putamen	UBERON:0001874	69.47	gold quality
left adrenal gland cortex	UBERON:0035825	69.44	gold quality
caudate nucleus	UBERON:0001873	69.39	gold quality
endocervix	UBERON:0000458	69.17	gold quality
left adrenal gland	UBERON:0001234	69.17	gold quality
spleen	UBERON:0002106	69.13	gold quality
body of uterus	UBERON:0009853	69.13	gold quality
gastrocnemius	UBERON:0001388	68.91	gold quality
amygdala	UBERON:0001876	68.89	gold quality
adult organism	UBERON:0007023	68.81	gold quality
omental fat pad	UBERON:0010414	68.57	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.89

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 3)

• ARMC12 promotes neuroblastoma progression through interaction with RBBP4. (PMID:30026490)
• ARMC12 regulates spatiotemporal mitochondrial dynamics during spermiogenesis and is required for male fertility. (PMID:33536340)
• Biallelic mutations in ARMC12 cause asthenozoospermia and multiple midpiece defects in humans and mice. (PMID:35534203)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	armc10	ENSDARG00000062960
mus_musculus	Armc12	ENSMUSG00000024223
rattus_norvegicus	Armc12	ENSRNOG00000000508
caenorhabditis_elegans		WBGENE00013456

Paralogs (10): ARMCX3 (ENSG00000102401), ARMCX5 (ENSG00000125962), ARMCX1 (ENSG00000126947), GPRASP2 (ENSG00000158301), ARMC10 (ENSG00000170632), ARMCX2 (ENSG00000184867), ARMCX4 (ENSG00000196440), GPRASP3 (ENSG00000198908), GPRASP1 (ENSG00000198932), ARMCX6 (ENSG00000198960)

Protein

Protein identifiers

Armadillo repeat-containing protein 12 — Q5T9G4 (reviewed: Q5T9G4)

All UniProt accessions (2): Q5T9G4, F8WC51

UniProt curated annotations — full annotation on UniProt →

Function. Essential for male fertility and sperm mitochondrial sheath formation. Required for proper mitochondrial elongation and coiling along the flagellum during the formation of the mitochondrial sheath. Facilitates the growth and aggressiveness of neuroblastoma cells. Increases the EZH2 activity and H3K27me3 levels in a RBBP4-dependent manner, and facilitates the enrichment of polycomb repressive complex 2 and H3K27me3 on gene promoters, resulting in transcriptional repression of tumor suppressors affecting the proliferation, invasion, and metastasis of tumor cells.

Subunit / interactions. Interacts with TBC1D15, TBC1D21, GK2 and IMMT. Interacts with VDAC2 and VDAC3 in a TBC1D21-dependent manner. Interacts (via ARM domains) with RBBP4.

Subcellular location. Nucleus. Mitochondrion outer membrane.

Tissue specificity. Expressed in testis. Highly expressed in the mid-piece of the elongated and late spermatids. Expressed at higher levels in neuroblastoma tissues and cell lines, than those of normal dorsal ganglia (at protein level). Expressed in breast cancer, colon cancer, hepatocellular carcinoma, lung cancer, pancreas cancer, prostate cancer, renal cancer and gastric cancer, but not in their normal counterparts.

Disease relevance. Spermatogenic failure 90 (SPGF90) [MIM:620744] An autosomal recessive male infertility disorder due to severely reduced progressive motility of sperm. The disease may be caused by variants affecting the gene represented in this entry.

Isoforms (3)

UniProt ID	Names	Canonical?
Q5T9G4-1	1	yes
Q5T9G4-2	2
Q5T9G4-3	3

RefSeq proteins (3): NP_001273503, NP_001273505, NP_659465 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR006911	ARM-rpt_dom	Domain
IPR011989	ARM-like	Homologous_superfamily
IPR016024	ARM-type_fold	Homologous_superfamily
IPR042834	Armc12	Family

Pfam: PF04826

UniProt features (11 total): repeat 3, sequence variant 3, splice variant 2, chain 1, mutagenesis site 1, region of interest 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q5T9G4-F1	86.08	0.72

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Mutagenesis-validated functional residues (1):

Position	Phenotype
190	loss of interaction with rbbp4.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 75 (showing top): GOBP_GROWTH, GOBP_MALE_GAMETE_GENERATION, CCANNAGRKGGC_UNKNOWN, GOBP_POSITIVE_REGULATION_OF_CELL_GROWTH, GOBP_CILIUM_ORGANIZATION, GOBP_CILIUM_MOVEMENT, GOBP_CILIUM_OR_FLAGELLUM_DEPENDENT_CELL_MOTILITY, GOCC_MITOCHONDRIAL_ENVELOPE, GOBP_ORGANELLE_ASSEMBLY, GOBP_CELLULAR_PROCESS_INVOLVED_IN_REPRODUCTION_IN_MULTICELLULAR_ORGANISM, GOBP_POSITIVE_REGULATION_OF_GROWTH, GOBP_DEVELOPMENTAL_PROCESS_INVOLVED_IN_REPRODUCTION, LEF1_Q6, GOBP_MOTILE_CILIUM_ASSEMBLY, GOBP_CELL_PROJECTION_ORGANIZATION

GO Biological Process (5): positive regulation of cell growth (GO:0030307), flagellated sperm motility (GO:0030317), sperm mitochondrial sheath assembly (GO:0120317), spermatogenesis (GO:0007283), cell differentiation (GO:0030154)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (4): nucleus (GO:0005634), mitochondrial outer membrane (GO:0005741), mitochondrion (GO:0005739), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
intracellular membrane-bounded organelle	2
regulation of cell growth	1
cell growth	1
positive regulation of growth	1
positive regulation of cellular process	1
cilium-dependent cell motility	1
cilium movement involved in cell motility	1
sperm motility	1
cellular component assembly	1
sperm flagellum assembly	1
developmental process involved in reproduction	1
male gamete generation	1
cellular developmental process	1
binding	1
mitochondrial membrane	1
organelle outer membrane	1
cytoplasm	1
cellular anatomical structure	1

Protein interactions and networks

STRING

538 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ARMC12	RBBP4	P31149	788
ARMC12	TBC1D21	Q8IYX1	611
ARMC12	ARMC1	Q9NVT9	587
ARMC12	TRIM7	Q9C029	459
ARMC12	KLHL40	Q2TBA0	459
ARMC12	C1orf226	A1L170	428
ARMC12	VDAC3	Q9Y277	426
ARMC12	FCRL5	Q96RD9	421
ARMC12	VWA8	A3KMH1	414
ARMC12	AGAP6	Q5VW22	413
ARMC12	TEX38	Q6PEX7	413
ARMC12	ADTRP	Q96IZ2	410
ARMC12	CCDC38	Q502W7	398
ARMC12	HS6ST3	Q8IZP7	394
ARMC12	CD177	Q8N6Q3	393

IntAct

2 interactions, top by confidence:

A	B	Type	Score
ARMC12	PTPRG	psi-mi:“MI:0914”(association)	0.350

BioGRID (67): RBBP4 (Affinity Capture-MS), ANXA2P2 (Affinity Capture-MS), APOC3 (Affinity Capture-MS), ATP5B (Affinity Capture-MS), CALML5 (Affinity Capture-MS), CORO1C (Affinity Capture-MS), CORO6 (Affinity Capture-MS), DDX39A (Affinity Capture-MS), DSG1 (Affinity Capture-MS), EEF1A2 (Affinity Capture-MS), EZH2 (Affinity Capture-MS), FABP5 (Affinity Capture-MS), FBLN1 (Affinity Capture-MS), HBA1 (Affinity Capture-MS), HIST1H1B (Affinity Capture-MS)

ESM2 similar proteins: A0A3L7I2I8, A0JMZ3, A5HK05, A7MB89, A7YWD2, O60733, O75031, O94829, O94955, P0C7A6, P42694, P49754, P97570, P97819, Q05AL1, Q1LVW0, Q29RM5, Q2KI54, Q2T9K6, Q3UFS0, Q3UJZ3, Q4V890, Q5KU39, Q5R6S3, Q5R974, Q5T9G4, Q5TYQ1, Q5VZK9, Q68FK4, Q6DFV5, Q6EDY6, Q6NYU2, Q6QI06, Q6R327, Q7T3P8, Q8C0T1, Q8CEF1, Q8IUR7, Q8NFZ0, Q91W86

Diamond homologs: Q5T9G4, Q80X86

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

64 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	3
Likely pathogenic	0
Uncertain significance	57
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (3)

Variant ID	HGVS	Classification
3024455	NM_001286574.2(ARMC12):c.635T>C (p.Leu212Pro)	Pathogenic
3024456	NM_001286574.2(ARMC12):c.632G>A (p.Arg211Gln)	Pathogenic
3024457	NM_001286574.2(ARMC12):c.686G>A (p.Cys229Tyr)	Pathogenic

SpliceAI

654 predictions. Top by Δscore:

Variant	Effect	Δscore
6:35737268:GCCC:G	donor_gain	1.0000
6:35737272:G:GG	donor_gain	1.0000
6:35747259:A:AG	acceptor_gain	1.0000
6:35747259:A:AT	acceptor_loss	1.0000
6:35747259:AG:A	acceptor_gain	1.0000
6:35747260:G:GG	acceptor_gain	1.0000
6:35747260:GG:G	acceptor_gain	1.0000
6:35747260:GGAA:G	acceptor_gain	1.0000
6:35747260:GGAAC:G	acceptor_gain	1.0000
6:35747412:A:AG	donor_gain	1.0000
6:35747413:G:GG	donor_gain	1.0000
6:35747444:G:GT	donor_gain	1.0000
6:35747481:GCACA:G	donor_gain	1.0000
6:35747486:G:GG	donor_gain	1.0000
6:35747570:A:AG	acceptor_gain	1.0000
6:35747571:T:G	acceptor_gain	1.0000
6:35747574:A:AG	acceptor_gain	1.0000
6:35747574:A:AT	acceptor_loss	1.0000
6:35747574:AG:A	acceptor_gain	1.0000
6:35747574:AGGT:A	acceptor_gain	1.0000
6:35747575:G:GA	acceptor_gain	1.0000
6:35747575:GG:G	acceptor_gain	1.0000
6:35747575:GGT:G	acceptor_gain	1.0000
6:35747575:GGTG:G	acceptor_gain	1.0000
6:35747575:GGTGC:G	acceptor_gain	1.0000
6:35747647:GG:G	donor_loss	1.0000
6:35747649:T:A	donor_loss	1.0000
6:35748533:CACA:C	acceptor_loss	1.0000
6:35748535:CA:C	acceptor_loss	1.0000
6:35748536:A:AG	acceptor_gain	1.0000

AlphaMissense

2203 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
6:35738475:T:C	L134P	0.997
6:35738132:T:C	L90P	0.996
6:35738462:G:C	A130P	0.996
6:35747328:T:C	L171P	0.996
6:35738466:T:C	L131P	0.995
6:35738484:T:C	F137S	0.995
6:35747334:T:C	L173P	0.995
6:35748728:T:C	L294P	0.995
6:35748602:T:C	L252P	0.994
6:35748620:T:C	L258P	0.994
6:35748761:T:A	V305D	0.994
6:35738147:G:C	R95P	0.992
6:35747328:T:A	L171H	0.992
6:35747376:T:C	L187P	0.992
6:35747637:T:C	L227P	0.992
6:35748772:G:C	A309P	0.992
6:35747328:T:G	L171R	0.991
6:35748602:T:A	L252Q	0.991
6:35748602:T:G	L252R	0.991
6:35748611:C:A	A255D	0.991
6:35748773:C:A	A309D	0.991
6:35738132:T:G	L90R	0.990
6:35747622:T:C	L222P	0.990
6:35748737:T:C	L297P	0.990
6:35738153:T:A	V97E	0.989
6:35747337:T:C	L174P	0.989
6:35748728:T:A	L294Q	0.989
6:35748728:T:G	L294R	0.989
6:35748697:T:C	F284L	0.988
6:35748699:T:A	F284L	0.988

dbSNP variants (sampled 300 via entrez): RS1000036435 (6:35741483 C>T), RS1000196976 (6:35741246 G>A,C), RS1000274524 (6:35736096 AG>A), RS1000407033 (6:35735821 G>A,T), RS1001066696 (6:35731851 C>A), RS1001359334 (6:35740627 C>G,T), RS1001390504 (6:35740935 T>C), RS1001563987 (6:35736182 G>A), RS1001626003 (6:35735208 A>C), RS1001644936 (6:35742225 GC>G), RS1001663604 (6:35731972 A>G), RS1001774630 (6:35730316 A>C,G), RS1001908287 (6:35735525 T>C), RS1001951849 (6:35731545 G>A,T), RS1002218342 (6:35732083 G>C)

Disease associations

OMIM: gene MIM:620377 | disease phenotypes: MIM:620744

GenCC curated gene-disease

Mondo (2): prostate cancer (MONDO:0008315), spermatogenic failure 90 (MONDO:0958242)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

7 total (7 of 7 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000798	Oligozoospermia
HP:0003251	Male infertility
HP:0011462	Young adult onset
HP:0030345	Abnormal circulating luteinizing hormone concentration
HP:0030346	Abnormal circulating follicle-stimulating hormone concentration
HP:0034011	Reduced progressive sperm motility

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST004617_27	Eosinophil percentage of granulocytes	4.000000e-09
GCST010561_4	Depression x herpes simplex 1 infection interaction	2.000000e-06
GCST90020025_724	Waist-to-hip ratio adjusted for BMI	1.000000e-09
GCST90020027_1146	Waist-hip index	8.000000e-11

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0007996	eosinophil percentage of granulocytes
EFO:0007036	herpes virus seropositivity
EFO:0007788	BMI-adjusted waist-hip ratio

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

9 total (human), top 9 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
ethyl-p-hydroxybenzoate	decreases expression	1
bisphenol S	affects cotreatment, decreases methylation	1
Fulvestrant	affects cotreatment, decreases methylation	1
Acetaminophen	decreases expression	1
Benzo(a)pyrene	decreases expression	1
Diethylhexyl Phthalate	decreases expression	1
Methylcholanthrene	affects binding, increases reaction	1
Silicon Dioxide	decreases expression	1
Dihydrotestosterone	increases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer